SB And Aviron Partner For EBV Vaccine
US biopharmaceutical company Aviron and SmithKline Beecham have joined forces for the development and commercialization of vaccines against Epstein-Barr virus, the causative agent in infectious mononucleosis.
Primarily, the collaboration will focus on an Aviron subunit vaccine currently in preclinical development. The firm's other vaccines are mainly live products. Responsibility for clinical trials, manufacturing and commercialization of the product will be taken by SB. In return, SB will have exclusive rights to produce and market any products resulting from the collaboration, including both therapeutic and prophylactic vaccines. Aviron and SB will collaborate on the distribution of the vaccine in the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze